Prospective trials of angiotensin receptor blockers: Beyond blood pressure control

Current Hypertension Reports

Volumn 2, Issue 2, 2000, Pages 163-164

  Siragy, Helmy M ^a   Carey, Robert M ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE; LOSARTAN; TETRAZOLE DERIVATIVE; VALINE; VALSARTAN;

DRUG ANTAGONISM; HEART INFARCTION; HUMAN; HYPERTENSION; REVIEW;

ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; LOSARTAN; MYOCARDIAL INFARCTION; RECEPTORS, ANGIOTENSIN; TETRAZOLES; VALINE;

EID: 0034169902     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-000-0076-1     Document Type: Review

References (7)

1. Zitnay C, Siragy HM: Action of angiotensin receptor subtypes on the renal tubules and vasculature: implications for volume homeostasis and atherosclerosis. Miner Electrolyte Metab 1998, 24(suppl 6):362-370.
2. Dahlof B, Devereux R, de Faire U, et al.: The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. Am J Hypertens 1997, 10: 705-713.
3. Mann J, Julius S: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press 1998, 7(suppl 3):176-183.
4. Julius S: Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation. Cardiology 1999, 91(suppl 1):8-13.
5. Cohn JN, Tognoni G, Glazer RD, et al.: Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail 1999, 5(suppl 2):155-160.
6. Cohn JN: Improving outcomes in congestive heart failure: Val-HeFT. Valsartan in Heart Failure Trial. Cardiology 1999, 91(suppl 1):19-22.
7. Dickstein K, Kjekshus J: Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am J Card 1999, 83(suppl 4):477-481.